澳大利亚给予Proteomics 2.2M研发退款,以推进早期疾病检测平台。 Australia grants Proteomics $2.2M R&D rebate to advance early-disease detection platform.

国际实验室从澳大利亚政府收到了220万美元的研发退款,资金来自515万美元合格研究支出的43.5%的税收奖励。 Proteomics International Laboratories has received a $2.2 million R&D rebate from the Australian government, funded by a 43.5% tax incentive on $5.15 million in qualifying research spending. 这笔资金将支持其Promarker平台的商业推出,该平台在出现症状之前的几年内检测糖尿病肾脏疾病、内分泌硬化症和食道癌等疾病。 The funds will support the commercial rollout of its Promarker platform, which detects diseases like diabetic kidney disease, endometriosis, and oesophageal cancer years before symptoms appear. 该公司计划在年终之前在澳大利亚启动内分泌硬化测试,并准备在新认可的实验室进入美国市场。 The company plans to launch its endometriosis test in Australia before year-end and prepare for U.S. market entry with a newly accredited lab. 目前正在进行哮喘、早期糖尿病并发症和其他状况的额外检测,现有的诊断已经通过远程保健和病理网络产生收入。 Additional tests for asthma, early diabetes complications, and other conditions are in development, with existing diagnostics already generating revenue through telehealth and pathology networks.